+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Residual leukemic cells in autologous marrow grafts do not significantly contribute to leukemia relapse after bone marrow transplantation



Residual leukemic cells in autologous marrow grafts do not significantly contribute to leukemia relapse after bone marrow transplantation



Experimental Hematology 16(6): 492




(PDF emailed within 1 workday: $29.90)

Accession: 029084772

Download citation: RISBibTeXText


Related references

The contribution of residual leukemic cells in the graft to leukemia relapse after autologous bone marrow transplantation: mathematical considerations. Leukemia 3(7): 530-534, 1989

Autologous bone marrow transplantation for CML in which retroviral markers are used to discriminate between relapse which arises from systemic disease remaining after preparative therapy versus relapse due to residual leukemia cells in autologous marrow: a pilot trial. The University of Texas M.D. Anderson Cancer Center. Human Gene Therapy 2(4): 359-376, 1991

Modeling autologous bone marrow transplantation in leukemia and the inhibition of leukemic cells in grafts. Eksperimental'naya Onkologiya 13(3): 39-42, 1991

Autologous bone marrow transplantation using the long term bone marrow culture system to purge residual leukemic cells. Gale, R P (Ed ) Ucla (University Of California-Los Angeles) Symposia on Molecular And Cellular Biology New Series, Vol 134 Acute Myelogenous Leukemia: Progress And Controversies; Wyeth-Ayerst-Ucla Western Workshop, Lake Lanier, Georgia, Usa, November 28-December 1, 1989 Xxvi+500p Wiley-Liss: New York, New York, Usa; Chichester, England, Uk Illus 433-440, 1990

Marrow purging in autologous bone marrow transplantation for t lineage acute lymphoblastic leukemia efficacy of ex vivo treatment with immunotoxins and 4 hydroperoxycyclophosphamide against fresh leukemic marrow progenitor cells. Blood 69(1): 361-366, 1987

Allogenic bone marrow transplantation versus autologous bone marrow transplantation for the treatment of childhood acute lymphoblastic leukemia in second remission after early marrow relapse. Blood 86(10 SUPPL 1): 939A, 1995

Bone marrow transfected with the IL-2 gene for reducing leukemic relapse following autologous bone marrow transplantation. Blood 90(10 SUPPL 1 PART 2): 418B, Nov 15, 1997

Bone marrow-resident memory T cells survive pretransplant chemotherapy and contribute to early immune reconstitution of patients with acute myeloid leukemia given mafosfamide-purged autologous bone marrow transplantation. Experimental Hematology 33(2): 212-218, 2005

Combination of hyperthermia with liquid marrow culture for purging leukemic marrow in vitro and application to autologous bone marrow transplantation in treatment of patients with acute leukemia. Experimental Hematology 22(8): 778, 1994

Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 83(10): 3068-3076, 1994

Residual leukemia cells present in the marrow cells infused during autologous transplants contribute to relapse following intensive systemic therapy. Journal of Investigative Medicine 43(SUPPL 2): 340A, 1995

Detection of minimal residual disease in peripheral blood stem cells from two acute myeloid leukemia patients with trisomy 8 predicts early relapse after autologous bone marrow transplantation. Cancer Genetics & Cytogenetics 133(1): 98-101, 2002

Allogeneic bone marrow transplantation for relapse after autologous bone marrow transplantation in lymphomas and acute leukemia. Blood 86(10 SUPPL 1): 969A, 1995

Autologous bone marrow transplantation in acute myeloid leukemia at relapse using monoclonal antibody-purged bone marrow CALGB Study 8882. Blood 86(10 SUPPL 1): 959A, 1995